Review
Open access
Oct 2026
Finerenone and SGLT2 Inhibitors in Cardiorenal Disease: A Phenotype-Based Approach to Nephroprotection
Background/Objectives: Patients with chronic kidney disease (CKD), although treated with optimal renin–angiotensin–aldosterone system (RAAS) blockade, remain at substantial residual risk of disease progression and cardiovascular events. The recent arrival of sodium-glucose cotransporter-2 (SGLT2) inhibitors, and non-st...
Chiara Serpico, Ettore Luisi, Mariarosaria Morello et al.
· Journal of Personalized Medi... · 0 citations